https://doi.org/10.55788/03fdc309
The lack of scientific guidance in treating children with paediatric post-COVID condition (PPCC) has been problematic. Ms Nadia Baalbaki (Emma Childrenās Hospital, the Netherlands) presented IP4C, an international collaboration of researchers, patient representatives, and physicians [1]. This study aimed to assess the currently available paediatric, international, long-COVID care programmes and compare the characteristics of their patient cohorts. A cross-sectional analysis from aggregated data collected by a survey explored topics such as the used definition for paediatric long COVID, the organisation of paediatric long-COVID clinics, and PPCC patientsā characteristics.
The study analysed aggregated data from long-COVID patients (n=431) from 17 cohorts in 13 different countries. The mean age of patients ranged from 6.5ā16.4 years. Most patients (>90%) had asymptomatic or mild acute COVID-19. Frequent long-COVID symptoms were fatigue, headaches, concentration difficulties, dyspnoea, and sleep disturbances. At least two-thirds of patients were symptomatic for more than 12 weeks (66.6ā100%), and 5ā37% of patients had severe limitations in daily life. Definitions for long-COVID varied primarily in duration of symptoms and the necessity of microbiologically-proven SARS-CoV-2 infection.
Most long-COVID care programmes consisted of real-life visits with multidisciplinary teams, including general paediatricians, paediatric lung specialists, cardiologists, infectiologists, physiotherapists, and psychologists. Medical investigations revealed substantial disparities in care between the programmes (e.g. spirometry performed in 0ā100% of patients).
- Brackel C, et al. Uniting Global Efforts on Pediatric Long-COVID: Results of theĀ International Post-COVID Condition in Children Collaboration (IP4C). Poster 601, ATS International Conference 2022, San Francisco, CA, USA, 13ā18 May.
Copyright Ā©2022 Medicom Medical Publishers
Posted on
Previous Article
« MANDALA and DENALI pattern success for albuterol-budesonide in asthma Next Article
Frailty prevalent 5 months following hospitalisation for COVID-19 »
« MANDALA and DENALI pattern success for albuterol-budesonide in asthma Next Article
Frailty prevalent 5 months following hospitalisation for COVID-19 »
Table of Contents: ATS 2022
Featured articles
Letter from the Editor
COVID-19
Nebulised aviptadil āfutileā in I-SPY COVID-19 trial
Lung transplantation after COVID-19-associated ARDS
Mesenchymal stem cells offer no benefit in COVID-19
Alpha-1 antitrypsin for ARDS secondary to severe COVID-19
Frailty prevalent 5 months following hospitalisation for COVID-19
Paediatric long COVID lacks definitions
Asthma Clinical Trial Updates
MANDALA and DENALI pattern success for albuterol-budesonide in asthma
ACOUSTICS data sounds good for adolescent asthma exacerbations
Type 2 asthma in children managed by dupilumab, despite atopic comorbidities
NAVIGATOR steers asthma patients to tezepelumab
High-intensity interval training slashes daily corticosteroids in asthma
Chronic Obstructive Pulmonary Disease
Threeās a crowd for triple therapy in COPD
Higher 1-year COPD mortality after hospitalisation for White patients
Reducing dyspnoea in chronic lung disease through weight loss
CT-evident mucus plugs in COPD associated with death
Home-based rehabilitation improves COPD: a randomised study
Highlighted Advances
Novel P2X3 antagonist can SOOTHE chronic cough
Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis
Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?
PAGANINI phase 2b data promising for eliapixant
POISE-3: Tranexamic acid for non-cardiac surgery
Obstructive sleep apnoea in most children with pulmonary hypertension
No screening evidence for COPD
Novel PDE4B inhibitor offers breakthrough for IPF
Hydrocortisone does not help preterm infants
CPAP temporarily supports pulmonary oxygenation in morbidly obese patients
ISAACC trial: CPAP controls blood pressure in ACS patients with severe OSA
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com